Publication Name	World Journal of Clinical Oncology
Manuscript ID	17857
Country	United States

Received	2015-03-27 08:47
Peer-Review Started	2015-03-28 19:28
To Make the First Decision	2015-04-27 15:29
Return for Revision	2015-04-30 16:33
Revised	2015-05-06 03:02
Second Decision	2015-06-12 16:35
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2015-07-08 15:30
Articles in Press	2015-07-08 15:30
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2015-07-23 15:13
Publish the Manuscript Online	2015-08-17 16:41

ISSN	2218-4333 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Minireviews
Article Title	Concurrent chemoradiation for high-risk prostate cancer
Manuscript Source	Invited Manuscript
All Author List	Benjamin T Cooper and Nicholas J Sanfilippo
Funding Agency and Grant Number
Corresponding Author	Nicholas Sanfilippo, MD, Department of Radiation Oncology, New York University School of Medicine, 160 East 34th Street, New York, NY 10016, United States. nicholas.sanfilippo@nyumc.org
Key Words	Prostate cancer; Chemoradiation; High-risk prostate cancer; Concurrent chemotherapy; Chem­otherapy; Intensity modulated radiation therapy
Core Tip	Over half of patients with high-risk prostate cancer will have a biochemical relapse within 5 years when treated primarily with radiotherapy as shown in multiple studies. One method that has been shown to improve local control, and in some disease sites overall survival, is the addition of chemotherapy to radiotherapy for definitive treatment. We review the safety and efficacy data of combined chemoradiation in patients with high risk adenocarcinoma of the prostate.
Publish Date	2015-08-17 16:41
Citation	Cooper BT, Sanfilippo NJ. Concurrent chemoradiation for high-risk prostate cancer. World J Clin Oncol 2015; 6(4): 35-42
URL	http://www.wjgnet.com/2218-4333/full/v6/i4/35.htm
DOI	http://dx.doi.org/10.5306/wjco.v6.i4.35

Full Article (PDF)	WJCO-6-35.pdf
Full Article (Word)	WJCO-6-35.doc
Manuscript File	17857-Review.docx
Answering Reviewers	17857-Answering reviewers.pdf
Audio Core Tip	17857-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	17857-Conflict-of-interest statement.pdf
Copyright License Agreement	17857-Copyright assignment.pdf
Peer-review Report	17857-Peer-review(s).pdf
Scientific Misconduct Check	17857-Scientific misconduct check.pdf
Scientific Editor Work List	17857-Scientific editor work list.pdf